IL166625A0 - Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer - Google Patents

Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Info

Publication number
IL166625A0
IL166625A0 IL16662505A IL16662505A IL166625A0 IL 166625 A0 IL166625 A0 IL 166625A0 IL 16662505 A IL16662505 A IL 16662505A IL 16662505 A IL16662505 A IL 16662505A IL 166625 A0 IL166625 A0 IL 166625A0
Authority
IL
Israel
Prior art keywords
cancer
treatment
combination
tyrosine kinase
kinase inhibitors
Prior art date
Application number
IL16662505A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL166625A0 publication Critical patent/IL166625A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16662505A 2002-08-09 2005-02-01 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer IL166625A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0218526.2A GB0218526D0 (en) 2002-08-09 2002-08-09 Combination therapy
PCT/GB2003/003390 WO2004014426A1 (en) 2002-08-09 2003-08-05 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Publications (1)

Publication Number Publication Date
IL166625A0 true IL166625A0 (en) 2006-01-15

Family

ID=9942013

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16662505A IL166625A0 (en) 2002-08-09 2005-02-01 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Country Status (14)

Country Link
US (2) US20050245549A1 (https=)
EP (1) EP1534338A1 (https=)
JP (1) JP2006500346A (https=)
KR (1) KR20050059060A (https=)
CN (1) CN100556456C (https=)
BR (1) BR0313117A (https=)
CA (1) CA2495489A1 (https=)
GB (1) GB0218526D0 (https=)
IL (1) IL166625A0 (https=)
MX (1) MXPA05001457A (https=)
NO (1) NO20050528L (https=)
NZ (1) NZ537754A (https=)
WO (1) WO2004014426A1 (https=)
ZA (1) ZA200501061B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301689B6 (cs) 1999-11-05 2010-05-26 Astrazeneca Ab Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
JP4608215B2 (ja) 2002-02-01 2011-01-12 アストラゼネカ アクチボラグ キナゾリン化合物
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
RU2007134908A (ru) * 2005-04-14 2009-05-20 Вайет (Us) Применение ингибитора активности киназы рецептора эпидермального фактора роста для лечения пациентов, невосприимчивых к гефитинибу
US20080219977A1 (en) * 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
AU2007299080B2 (en) * 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
PL2451445T3 (pl) 2009-07-06 2019-09-30 Boehringer Ingelheim International Gmbh Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
GB201516905D0 (en) * 2015-09-24 2015-11-11 Stratified Medical Ltd Treatment of Neurodegenerative diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ATE369894T1 (de) * 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
DE60311788T2 (de) * 2002-04-16 2007-11-22 Astrazeneca Ab Kombinationstherapie zur behandlung von krebs
KR20050056190A (ko) * 2002-08-09 2005-06-14 아스트라제네카 아베 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed

Also Published As

Publication number Publication date
US20050245549A1 (en) 2005-11-03
ZA200501061B (en) 2007-01-31
AU2003252976A1 (en) 2004-02-25
CN100556456C (zh) 2009-11-04
WO2004014426A1 (en) 2004-02-19
CA2495489A1 (en) 2004-02-19
US20100130493A1 (en) 2010-05-27
NZ537754A (en) 2008-02-29
JP2006500346A (ja) 2006-01-05
NO20050528L (no) 2005-05-03
MXPA05001457A (es) 2005-06-06
EP1534338A1 (en) 2005-06-01
CN1674938A (zh) 2005-09-28
GB0218526D0 (en) 2002-09-18
BR0313117A (pt) 2005-07-05
KR20050059060A (ko) 2005-06-17

Similar Documents

Publication Publication Date Title
IL166625A0 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
HUP0302544A3 (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
AU2003299651A8 (en) Tyrosine kinase inhibitors
IL198996A0 (en) Inhibitors of tyrosine kinases
PT1686999E (pt) Derivados de pirazole como inibidores de receptores tirosina-cinases
SI1667991T1 (sl) Kinazolinski derivati kot inhibitorji tirozin kinaze
IL174258A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
AU2003298942A8 (en) Tyrosine kinase inhibitors
AU2003282891A8 (en) Novel tyrosine kinases inhibitors
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
EP1581539A4 (en) NEW TYROSINE KINASE HEMMER
IL173593A0 (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
PT1531819E (pt) Utilização de inibidores da i capa b cinase na terapia da dor
AU2003273842A8 (en) Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibitors
AU2003275282A8 (en) Novel tyrosine kinase inhibitors
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
IL183448A0 (en) Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy
IL173483A0 (en) Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases
SI1562955T1 (sl) Derivati kinazolina kot inhibitorji Src-triozin kinaze
SI1660090T1 (sl) Kinazolinski analogi kot inhibitorji receptorjev tirozin kinaze
HK1076745A (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
GB2410744B (en) Kinase inhibitors for the treatment of disease
AU2003219420A1 (en) Pdgf receptor tyrosine kinase inhibitors for the treatment of polycythemia vera
GB0201384D0 (en) Tyrosine kinase inhibitors